Blood alterations preceding clinical manifestation of glioblastoma

Cancer Investigation

Volumn 30, Issue 9, 2012, Pages 625-629

  Ilhan Mutlu, Aysegül ^a,d   Wagner, Ludwig ^a,d   Wöhrer, Adelheid ^a,d   Jungwirth, Susanne ^b   Marosi, Christine ^a,d   Fischer, Peter ^b,c   Preusser, Matthias ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c DANUBE HOSPITAL   (Austria)

^d Austrian Breast and Colorectal Cancer Study Group   (Austria)

Author keywords

Aging; Biomarker; Follow up; Glioblastoma; Micro RNA

Indexed keywords

MICRORNA; MICRORNA 128; MICRORNA 21; MICRORNA 342 3P; NEUROPEPTIDE Y; PROTEIN S100B; SECRETAGOGIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICRORNAS;

EID: 84867738616     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.725443     Document Type: Article

References (18)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO Classification of Tumours of the Ccentral Nervous System. Lyon: IARC, 2007.
2. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain: J Neurol 2007;130:3336-3341.
3. Fischer P, Jungwirth S, Krampla W, Weissgram S, Kirchmeyr W, Schreiber W, Huber K, Rainer M, Bauer P, Tragl KH. Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation. J Neural Trans Suppl 2002;62:105-116.
4. Gartner W, Ilhan A, Neziri D, Base W, Weissel M, Wohrer A, Heinzl H, Waldhor T, Wagner L, Preusser M. Elevated blood markers 1 year before manifestation of malignant glioma. Neurooncol 2010;12:1004-1008.
5. Boyerinas B, Park SM, Hau A, Murmann AE, PeterME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010;17:F19-F36.
6. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X, Zhao Y. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 2011;41:1245-1253.
7. Ilhan-Mutlu A, Wagner L, Ẅohrer A, Furtner J, Widhalm G, Marosi C, Preusser M. Plasma microRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 2012;30(8):615-621.
8. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 2011;118:449-457.
9. Wohrer A,Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K,Hainfellner JA.The Austrian brain tumour registry: a cooperativeway to establish a populationbased brain tumour registry. J Neuro-Oncol 2009;95:401-411.
10. GartnerW, LangW, Leutmetzer F, Domanovits H,WaldhauslW, Wagner L. Cerebral expression and serumdetectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex 2001;11:1161-1169.
11. Vasilescu C, Rossi S, ShimizuM, Tudor S,Veronese A, Ferracin M, NicolosoMS, BarbarottoE, PopaM, StanciuleaO, FernandezMH, Tulbure D, Bueso-Ramos CE, Negrini M, Calin GA. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PloS One 2009;4:e7405.
12. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germano A, Vita G, Tomasello F. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neuro-Oncol 2009;93:325-332.
13. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008;28:5369-5380.
14. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R. Current concepts andmanagement of glioblastoma. Ann Neurol 2011;70:9-21.
15. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010;1352:255-264.
16. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-6033.
17. Hodges GJ, Jackson DN, Mattar L, Johnson JM, Shoemaker JK. Neuropeptide Y and neurovascular control in skeletal muscle and skin. Am J Physiol Regulatory Integrative Comp Physiol 2009;297:R546-R555.
18. Attems J, Preusser M, Grosinger-Quass M, Wagner L, Lintner F, Jellinger K. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease. Neuropathol Appl Neurobiol 2008;34:23-32.